A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model

Journal of Pharmacological Sciences

Volumn 133, Issue 1, 2017, Pages 25-33

  Ito, Misato ^a   Yamazaki, Shunji ^a   Yamagami, Kaoru ^a   Kuno, Masako ^a   Morita, Yoshiaki ^a   Okuma, Kenji ^a   Nakamura, Koji ^a   Chida, Noboru ^a   Inami, Masamichi ^a   Inoue, Takayuki ^a   Shirakami, Shohei ^a   Higashi, Yasuyuki ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Adjuvant induced arthritis; ASP015K; Janus kinase; Peficitinib; Rheumatoid arthritis

Indexed keywords

INTERLEUKIN 2; JANUS KINASE 1; JANUS KINASE 3; PEFICITINIB; STAT5 PROTEIN; TOFACITINIB; 4-((5-HYDROXY-2-ADAMANTYL)AMINO)-1H-PYRROLO(2,3-B)PYRIDINE-5-CARBOXAMIDE; ADAMANTANE; IMMUNOLOGICAL ADJUVANT; JAK1 PROTEIN, RAT; JAK3 PROTEIN, RAT; NICOTINAMIDE;

ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG STRUCTURE; EX VIVO STUDY; FEMALE; HUMAN; IC50; IN VITRO STUDY; IN VIVO STUDY; LEWIS RAT; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; T LYMPHOCYTE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, EXPERIMENTAL; BLOOD; CELL PROLIFERATION; CHEMICALLY INDUCED; DRUG EFFECTS; METABOLISM; ORAL DRUG ADMINISTRATION; PARENTERAL DRUG ADMINISTRATION; PHOSPHORYLATION; PHYSIOLOGY;

ADAMANTANE; ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; ARTHRITIS, EXPERIMENTAL; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, PARENTERAL; JANUS KINASE 1; JANUS KINASE 3; MALE; NIACINAMIDE; PHOSPHORYLATION; RATS; STAT5 TRANSCRIPTION FACTOR; T-LYMPHOCYTES;

EID: 85009785491     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1016/j.jphs.2016.12.001     Document Type: Article

References (26)

1. (1) Imada, K., Leonard, W.J., The Jak-STAT pathway. Mol Immunol 37 (2000), 1–11.
2. (2) Leonard, W.J., Lin, J.X., Cytokine receptor signaling pathways. J Allergy Clin Immunol 105 (2000), 877–888.
3. (3) Sakuma, S., Nishigaki, F., Magari, K., Ogawa, T., Miyata, S., Ohkubo, Y., et al. FK506 is superior to methotrexate in therapeutic effects on advanced stage of rat adjuvant-induced arthritis. Inflamm Res 50 (2001), 509–514.
4. (4) Ghoreschi, K., Laurence, A., O'Shea, J.J., Janus kinases in immune cell signaling. Immunol Rev 228 (2009), 273–287.
5. (5) Benson, J.M., Peritt, D., Scallon, B.J., Heavner, G.A., Shealy, D.J., Giles-Komar, J.M., et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs 3 (2011), 535–545.
6. (6) Changelian, P.S., Flanagan, M.E., Ball, D.J., Kent, C.R., Magnuson, K.S., Martin, W.H., et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302 (2003), 875–878.
7. (7) Paniagua, R., Si, M., Flores, M.G., Rousvoal, G., Zhang, S., Aalami, O., et al. Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts. Transplantation 80 (2005), 1283–1292.
8. (8) Walsh, N.C., Gravallese, E.M., Bone remodeling in rheumatic disease: a question of balance. Immunol Rev 233 (2010), 301–312.
9. (9) Moelants, E.A., Mortier, A., Van Damme, J., Proost, P., Regulation of TNF-α with a focus on rheumatoid arthritis. Immunol Cell Biol 91 (2013), 393–401.
10. (10) Smolen, J.S., Beaulieu, A., Rubbert-Roth, A., Ramos-Remus, C., Rovensky, J., Alecock, E., et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371 (2008), 987–997.
11. (11) Bresnihan, B., Alvaro-Gracia, J.M., Cobby, M., Doherty, M., Domljan, Z., Emery, P., et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41 (1998), 2196–2204.
12. (12) Khraishi, M., Comparative overview of safety of the biologics in rheumatoid arthritis. J Rheumatol 82 (2009), 25–32.
13. (13) van Schouwenburg, P.A., Rispens, T., Wolbink, G.J., Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 9 (2013), 164–172.
14. (14) Chakravarty, S.D., Poulikakos, P.I., Ivashkiv, L.B., Salmon, J.E., Kalliolias, G.D., Kinase inhibitors: a new tool for the treatment of rheumatoid arthritis. Clin Immunol 148 (2013), 66–78.
15. (15) O'Shea, J.J., Kontzias, A., Yamaoka, K., Tanaka, Y., Laurence, A., Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 72 (2013), ii111–ii115.
16. (16) Clark, J.D., Flanagan, M.E., Telliez, J.B., Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem 57 (2014), 5023–5038.
17. (17) Billingham, M.E., Models of arthritis and the search for anti-arthritic drugs. Pharmacol Ther 21 (1983), 389–428.
18. (18) Hegen, M., Keith, J.C. Jr., Collins, M., Nickerson-Nutter, C.L., Utility of animal models for identification of potential therapeutics for rheumatoid arthritis. Ann Rheum Dis 67 (2008), 1505–1515.
19. (19) Magari, K., Nishigaki, F., Sasakawa, T., Ogawa, T., Miyata, S., Ohkubo, Y., et al. Anti-arthritic properties of FK506 on collagen-induced arthritis in rats. Inflamm Res 52 (2003), 524–529.
20. (20) Smith-Oliver, T., Noel, L.S., Stimpson, S.S., Yarnall, D.P., Connolly, K.M., Elevated levels of TNF in the joints of adjuvant arthritic rats. Cytokine 5 (1993), 298–304.
21. (21) Szekanecz, Z., Halloran, M.M., Volin, M.V., Woods, J.M., Strieter, R.M., Kenneth Haines, G. 3rd, et al. Temporal expression of inflammatory cytokines and chemokines in rat adjuvant-induced arthritis. Arthritis Rheum 43 (2000), 1266–1277.
22. (22) Carlson, R.P., Hartman, D.A., Ochalski, S.J., Zimmerman, J.L., Glaser, K.B., Sirolimus (rapamycin, Rapamune) and combination therapy with cyclosporin A in the rat developing adjuvant arthritis model: correlation with blood levels and the effects of different oral formulations. Inflamm Res 47 (1998), 339–344.
23. + T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother 28 (2005), 120–128.
24. (24) Tanaka, S., Regulation of bone destruction in rheumatoid arthritis through RANKL-RANK pathways. World J Orthop 4 (2013), 1–6.
25. (25) Schett, G., Gravallese, E., Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol 8 (2012), 656–664.
26. (26) LaBranche, T.P., Jesson, M.I., Radi, Z.A., Storer, C.E., Guzova, J.A., Bonar, S.L., et al. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum 64 (2012), 3531–3542.